User:Mr. Ibrahem/Reslizumab

Reslizumab, sold under the brand name Cinqair among others, is a medication used for eosinophilic asthma uncontrolled by other measures. It is used by injection into a vein. Use is not recommended in Scotland due to a lack of cost benefit.

Common side effects include allergic rhinitis, shortness of breath, and muscle damage. Other side effects may include cancer and anaphylaxis. It is a monoclonal antibody that attaches to and blocks interleukin-5 (IL-5).

Reslizumab was approved for medical use in the United States and Europe in 2016. In the United States a 100 mg vial costs about 1,050 USD as of 2021. This amount in the United Kingdom costs the NHS about £500.